Homo sapiens Raw sequence reads
Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD5 chimeric antigen receptor (CAR) T-cell safety and efficacy in patients with r/r T-ALL.